Forward Pharma

43 articles about Forward Pharma

• Forward Pharma A/S Announces Termination of its American Depositary Receipts (“ADR”) Facility

  1/8/2024

  Forward Pharma A/S announced that its Board of Directors has approved a termination of the Deposit Agreement, dated October 14, 2014, among Forward Pharma A/S, the Depositary Bank of New York Mellon, and Owners and Holders of ADRs.

• Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares

  6/7/2023

  Forward Pharma A/S (OTC:FWPAY) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of New York Mellon as depositary, from 14 ordinary shares per ADS to 4000 ordinary shares per ADS.

• Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

  12/19/2022

  Forward Pharma A/S, announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted.

• Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review

  12/6/2022

  Forward Pharma A/S, announced that the Enlarged Board of Appeal of the European Patent Office has denied Forward’s petition for review of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding.

• Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021

  4/8/2022

  Forward Pharma A/S, reported consolidated financial results for the year ended December 31, 2021.

• Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020

  4/14/2021

  Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020. Our net loss for the year ended December 31, 2020 was $6.4 million, or $0.07 per share, versus a net loss of $4.2 million, or $0.04 per share for the year ended December 31, 2019. 

• Forward Pharma Announces New Date for the EP2801355 Appeal Hearing due to COVID-19

  5/12/2020

  Forward Pharma A/S, announced that due to current precautionary measures against the spread of the novel coronavirus, the Technical Board of Appeal of the European Patent Office has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent.

• Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2019

  4/24/2020

  Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial and operating results for the year ended December 31, 2019.

• Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent

  1/29/2018

  The EPO Opposition Division revoked the ’355 patent after considering third-party oppositions from several opponents

• Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit

  12/22/2017

  Forward Pharma today announced the filing of its reply brief to the U.S. Court of Appeals for the Federal Circuit in the appeal of the PTAB's decision in the interference proceeding between the Forward 11/576,871 patent application and an issued Biogen patent.

• Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018

  11/30/2017

  The filing will become publicly available via the European Patent Register.

• Forward Pharma Announces Completion of Corporate Restructuring Plan

  11/27/2017

  Forward Pharma shareholders are urged to read the restructuring agreements and the License Agreement in their entirety as well as other risk factors as outlined in the annual report for the year ended December 31, 2016, as filed under a form 20-F with the SEC.

• Forward Pharma Files Opening Brief In The Appeal Of The U.S. Patent Interference To The Federal Circuit

  9/6/2017

• Forward Pharma Board Of Directors Approves Capital Reduction And Returns EUR 917.7 Million To Shareholders

  9/1/2017

• Forward Pharma Obtains Shareholder Approval Of The Planned Capital Reduction At The Extraordinary General Meeting

  8/3/2017

• Forward Pharma Announces Planned Distribution Of EUR 19.45 Per Share To Shareholders

  7/18/2017

• Forward Pharma Appeals The Initial Decision In The U.S. Patent Interference To The Federal Circuit

  5/31/2017

• Forward Pharma CFO and Two VPs Step Down, Will Cut More Jobs Bringing the Number of Full-Time Employees to Seven

  5/1/2017

• Forward Pharma Reports Fourth Quarter And Year End 2016 Financial And Operational Results

  4/19/2017

• Forward Pharma Intends To Appeal Decision In Patent Interference Proceeding With Biogen

  4/3/2017